A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Saroglitazar (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Acronyms EPICS
- Sponsors Zydus Cadila
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.
- 27 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
- 18 Apr 2017 New trial record